Cardiomyopathy Management

Introduction

If you or a family member has been diagnosed with cardiomyopathy, you are probably trying to understand what comes next. Cardiomyopathy is a disease of the heart muscle itself — the muscle becomes weakened, thickened, stiff, or scarred, and the heart cannot pump or fill with blood the way it should. The diagnosis can feel heavy, but cardiomyopathy is now widely treated as a long-term, manageable condition rather than a sudden crisis.

Cardiomyopathy management is not a single operation or a one-time treatment. It is an ongoing plan that combines medications, lifestyle changes, monitoring, and — for some people — implanted devices or surgery. The plan is shaped by the type of cardiomyopathy you have, how the heart is functioning, your symptoms, your family history, and other health conditions you may live with.

This guide explains what cardiomyopathy is, how the different types are managed, what daily life looks like, when devices or surgery may be considered, what to watch for over time, and how cardiomyopathy is approached in children. It is written for patients and families who already have a diagnosis and are planning the next phase of care.

What Is Cardiomyopathy?

Cardiomyopathy is the medical term for disease of the heart muscle (the myocardium). The heart is a muscular pump with four chambers. To work well, the muscle must contract strongly to push blood out, and relax fully to let blood back in. In cardiomyopathy, one or both of these jobs is disturbed.

Some cardiomyopathies develop because of genetic changes inherited from a parent. Others develop after a long period of high blood pressure, after a viral infection of the heart muscle (myocarditis), after pregnancy (peripartum cardiomyopathy), as a result of long-term alcohol use, after certain cancer treatments, or from other illnesses that affect the heart muscle. In many people, no single cause is identified, and the condition is called idiopathic.

Doctors use the term “ejection fraction” (EF) to describe how much blood the main pumping chamber (the left ventricle) pushes out with each beat. A normal EF is around 55 to 70 percent. In some cardiomyopathies the EF is reduced; in others it can be normal even though the muscle is diseased. EF is one of the main measurements your cardiology team will track over time.

Anatomical cross-section of the heart showing: ① left ventricle, ② right ventricle, ③ left atrium, ④ right atrium, ⑤ aortic valve, ⑥ mitral valve.

*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.

Types of Cardiomyopathy

Dilated Cardiomyopathy (DCM)

In dilated cardiomyopathy, the main pumping chamber stretches and becomes thinner. The heart looks larger on imaging, but it pumps less effectively. DCM is the most common reason for heart failure with reduced ejection fraction. Causes include genetic factors, viral infection, alcohol, certain chemotherapy medications, uncontrolled high blood pressure, and pregnancy-related changes. In many cases the cause is not identified. Management focuses on heart failure medications, lifestyle changes, and — in selected patients — devices.

Hypertrophic Cardiomyopathy (HCM)

In hypertrophic cardiomyopathy, the heart muscle becomes abnormally thick, particularly the wall between the two main chambers. This thickening can make the chamber stiff so it does not fill easily, and in some people it can block the flow of blood leaving the heart (called obstructive HCM). HCM is the most common inherited heart condition and runs in families. Management focuses on relieving obstruction, controlling rhythm, identifying who is at higher risk of dangerous arrhythmias, and screening close relatives.

Cross-sections comparing: ① normal heart, ② dilated cardiomyopathy (enlarged, thin-walled chamber), ③ hypertrophic cardiomyopathy (thickened septum), ④ restrictive cardiomyopathy (stiff, rigid walls), ⑤ arrhythmogenic cardiomyopathy (fibrous-fatty tissue replacement).

*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.

Restrictive Cardiomyopathy

In restrictive cardiomyopathy, the heart muscle becomes stiff and cannot relax properly between beats. Pumping strength may be preserved at first, but the chambers do not fill well, and pressure backs up into the lungs and the rest of the body. Restrictive cardiomyopathy can be caused by conditions that deposit abnormal proteins or substances in the heart, such as amyloidosis, or by scarring after radiation or certain inflammatory diseases. Management focuses on the underlying cause where one can be treated, on controlling fluid overload, and on managing rhythm problems.

Arrhythmogenic Cardiomyopathy

In arrhythmogenic cardiomyopathy (sometimes called arrhythmogenic right ventricular cardiomyopathy, or ARVC), areas of normal heart muscle are gradually replaced by fibrous or fatty tissue. This makes the heart prone to dangerous rhythm disturbances and, over time, to weakening of the pumping function. It is usually inherited. Management focuses on reducing the risk of dangerous arrhythmias, often with medication and an implantable device, and on limiting intense exercise, which can accelerate the disease.

Other Forms

You may also hear terms such as peripartum cardiomyopathy (a form of DCM occurring late in pregnancy or after delivery), takotsubo cardiomyopathy or “stress cardiomyopathy” (a usually reversible weakening of the heart triggered by emotional or physical stress), and ischaemic cardiomyopathy (heart muscle weakening caused by blocked coronary arteries and previous heart attacks). Each has its own management considerations alongside the general principles described below.

Causes and Risk Factors

Understanding what caused or contributed to your cardiomyopathy helps shape long-term care. Common contributors include:

• Genetics. Many cardiomyopathies have an inherited component, especially HCM, ARVC, and a meaningful share of DCM. Your cardiologist may recommend genetic testing and screening of close relatives.
• Long-standing high blood pressure. Years of untreated hypertension can thicken and stiffen the heart muscle.
• Coronary artery disease. Previous heart attacks can leave areas of weakened or scarred muscle.
• Viral infections of the heart. Myocarditis can leave behind a weakened heart muscle in some patients.
• Alcohol and recreational drugs. Long-term heavy alcohol use and certain stimulants can weaken the heart.
• Chemotherapy and chest radiation. Some cancer treatments can affect the heart muscle, sometimes years later.
• Pregnancy. Peripartum cardiomyopathy can occur late in pregnancy or in the months after delivery.
• Metabolic and storage diseases. Conditions such as amyloidosis, sarcoidosis, haemochromatosis, and certain thyroid disorders can affect the heart muscle.
• Uncontrolled diabetes. Long-term diabetes contributes to heart muscle disease in several ways.

For many patients, no single cause is identified. This does not change the importance of structured long-term management.

Signs of Worsening to Watch For

Because you already have a diagnosis, the most useful symptom awareness is recognising changes that suggest your cardiomyopathy may be worsening or that complications are developing. Tell your cardiology team promptly if you notice:

• New or worsening shortness of breath, especially with activities you used to manage easily, or breathlessness when lying flat
• Waking at night feeling short of breath
• New swelling of the ankles, legs, or abdomen
• A sudden weight gain of more than 1 to 2 kg over a couple of days, which often reflects fluid retention
• Increasing fatigue or reduced exercise tolerance
• New palpitations, a racing heart, or a feeling that the heart is skipping or pausing
• Episodes of dizziness, near-fainting, or fainting — especially during exertion
• Persistent cough, particularly when lying down
• Chest pain or pressure

Sudden severe breathlessness, chest pain, fainting, or loss of consciousness needs emergency medical care.

Diagnosis and Ongoing Assessment

Even after the initial diagnosis, testing continues throughout the management of cardiomyopathy. These tests help your team understand how the heart is responding to treatment and whether the plan needs to change.

Common Tests

• Echocardiogram (echo). An ultrasound of the heart that measures chamber size, wall thickness, ejection fraction, and valve function. This is usually the main tool for following cardiomyopathy over time.
• Electrocardiogram (ECG). A short recording of the heart’s electrical activity, used to check rhythm and look for signs of strain or thickening.
• Cardiac MRI. A detailed scan that can show scarring and infiltration of the heart muscle and helps distinguish between cardiomyopathy types.
• Ambulatory rhythm monitoring. Wearable monitors (Holter, patch monitors, or implantable loop recorders) that record the heartbeat over hours, days, or longer to detect arrhythmias.
• Exercise testing. Walking on a treadmill or pedalling a bike, sometimes with imaging or breathing measurements, to assess functional capacity and look for exertion-related changes.
• Blood tests. Including NT-proBNP or BNP (markers of heart strain), kidney and electrolyte levels, thyroid function, iron studies, and tests for specific conditions such as amyloidosis when suspected.
• Cardiac catheterisation. A thin tube passed into the heart through a blood vessel to measure pressures and look at the coronary arteries when relevant.
• Genetic testing. Recommended in many inherited cardiomyopathies and may guide screening of family members.

Testing is not done all at once. Your cardiologist will decide which tests to repeat and how often based on the type of cardiomyopathy, your symptoms, and any new findings.

Treatment and Management

Modern cardiomyopathy management combines several layers of treatment. The specific combination depends on the type of cardiomyopathy, the ejection fraction, the symptoms, and other health conditions. The aim is to relieve symptoms, slow progression, reduce the risk of dangerous rhythm disturbances and clots, and prolong life.

Medications

Diagram illustrating the four pillars of heart failure medication: ① ARNI / ACE inhibitor / ARB (reduces cardiac workload), ② beta blocker (slows heart rate, protects muscle), ③ mineralocorticoid receptor antagonist (reduces fluid overload), ④ SGLT2 inhibitor (cardioprotective and diuretic effects).

*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.

Medications are the foundation of cardiomyopathy management for most patients. For heart failure with reduced ejection fraction — which is common in dilated and ischaemic cardiomyopathy — current AHA/ACC/HFSA and ESC guidelines describe four main classes of medication as the cornerstones of treatment, often called “four pillars”:

• Renin-angiotensin system blockers. This group includes ARNI (angiotensin receptor–neprilysin inhibitor, such as sacubitril/valsartan), ACE inhibitors, or angiotensin receptor blockers (ARBs). They help the heart pump more easily and slow progression.
• Beta blockers. Slow the heart rate and protect the heart muscle from overstimulation.
• Mineralocorticoid receptor antagonists (MRAs). Such as spironolactone or eplerenone, which reduce fluid overload and improve survival in selected patients.
• SGLT2 inhibitors. A group of medications originally developed for diabetes that have been shown to benefit many patients with heart failure, with or without diabetes.

Other medications used depending on the situation include diuretics (“water tablets”) to control fluid retention, ivabradine to slow heart rate in selected patients, digoxin in some cases, and anticoagulants (blood thinners) when there is atrial fibrillation or a high risk of clots.

For hypertrophic cardiomyopathy, the medication approach is different. Beta blockers or certain calcium channel blockers are commonly used to ease symptoms and reduce obstruction. A newer class of medication called cardiac myosin inhibitors (such as mavacamten) is increasingly used for obstructive HCM in line with current AHA/ACC guidance. ACE inhibitors and ARNIs are generally avoided in obstructive HCM because they can worsen the obstruction.

For restrictive cardiomyopathy, treatment is directed at the underlying cause when one can be identified and treated — for example, specific therapies for transthyretin amyloidosis. Diuretics are used carefully to manage fluid.

For arrhythmogenic cardiomyopathy, beta blockers and antiarrhythmic medications are often used to reduce the burden of rhythm disturbances.

Medication is built up gradually, with doses adjusted based on how you tolerate them, blood pressure, kidney function, and potassium levels. Reaching the target dose can take weeks to months. Skipping doses or stopping medication on your own can lead to rapid worsening — if a medication is not agreeing with you, talk to your team rather than stopping it.

Device Therapy

For some patients with cardiomyopathy, implanted devices are an important part of management.

• Implantable cardioverter-defibrillator (ICD). A small device placed under the skin near the collarbone, with leads that reach the heart. It can detect dangerous fast rhythms and deliver a shock to restore a normal beat. ICDs are considered for patients at higher risk of sudden cardiac death — for example, certain patients with significantly reduced ejection fraction, specific high-risk features of HCM or ARVC, or a history of resuscitated cardiac arrest.
• Cardiac resynchronisation therapy (CRT). A specialised pacemaker that coordinates the contraction of the heart’s two main pumping chambers. It is used in selected patients with reduced ejection fraction whose ECG shows a specific pattern of delayed electrical conduction.
• Pacemakers. Used when the heart rhythm is too slow or when medications used to control fast rhythms result in slow ones.

Schematic showing implanted cardiac devices: ① ICD generator pocket below the collarbone, ② right ventricular lead, ③ right atrial lead, ④ left ventricular CRT lead via coronary sinus, ⑤ shocking coil in the right ventricle.

*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.

Procedures and Surgery

Some patients with cardiomyopathy benefit from procedures or surgery aimed at specific problems:

• Septal reduction therapy in obstructive HCM. When medications do not control symptoms from obstruction, options include surgical septal myectomy (an operation to remove a portion of the thickened muscle) or alcohol septal ablation (a catheter-based procedure that shrinks the thickened area). Major guidelines describe these as options in symptomatic obstructive HCM not responding to medical therapy.
• Catheter ablation for arrhythmias. A procedure that uses energy delivered through a catheter to interrupt the electrical short-circuits causing rhythm problems, particularly atrial fibrillation or ventricular arrhythmias.
• Coronary revascularisation. In ischaemic cardiomyopathy, angioplasty with stents or bypass surgery may be considered to restore blood flow to areas of the heart muscle.
• Valve repair or replacement. Cardiomyopathy can cause the heart valves to leak. Repair or replacement is sometimes part of the overall plan.
• Mechanical circulatory support. In advanced heart failure, devices called left ventricular assist devices (LVADs) can help the heart pump — either as a long-term solution or as a bridge to transplant.
• Heart transplantation. For carefully selected patients with end-stage cardiomyopathy who have not responded to other treatments, heart transplant offers a chance at long-term survival and quality of life.

Comparison of septal reduction techniques in obstructive hypertrophic cardiomyopathy: ① thickened interventricular septum causing obstruction, ② surgical myectomy — portion of septum removed, ③ alcohol ablation catheter position, ④ targeted area of septal tissue shrinkage after ablation.

*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.

Cardiac Rehabilitation

Cardiac rehabilitation is a structured programme of supervised exercise, education, and support, usually delivered over several weeks. It is commonly recommended for stable patients with cardiomyopathy and heart failure. Studies show benefits in exercise capacity, quality of life, and hospital admissions. Rehabilitation is usually tailored to the individual — the type and intensity of exercise differs across cardiomyopathy types and is adjusted to your heart function and rhythm.

Lifestyle and Self-Management

What you do day to day is a meaningful part of cardiomyopathy management. The habits below are commonly recommended by cardiology teams.

Diet and Fluid

• Lower salt intake. Reducing dietary salt helps control fluid retention and blood pressure. Most guidelines suggest limiting added salt and salty processed foods.
• Watch fluid intake if advised. Some patients with heart failure are asked to limit total daily fluids. This is individualised — do not restrict fluid on your own without discussing it.
• Eat a heart-healthy pattern. Plenty of vegetables, fruits, whole grains, legumes, fish, and healthy oils, with less red and processed meat. A Mediterranean-style pattern is often recommended.
• Limit or avoid alcohol. Alcohol can weaken the heart muscle directly and trigger rhythm problems. In alcohol-related cardiomyopathy, complete abstinence is recommended.
• Avoid stimulants. Recreational drugs, certain weight-loss supplements, and very high caffeine intake can worsen cardiomyopathy.

Physical Activity

Most patients with cardiomyopathy are encouraged to be physically active at a level appropriate to their condition. Regular moderate activity — such as walking — supports overall health and reduces symptoms in many people. However, activity recommendations differ across cardiomyopathy types:

• In dilated cardiomyopathy and stable heart failure, moderate aerobic exercise and light resistance training are generally encouraged, often within a cardiac rehabilitation programme.
• In hypertrophic cardiomyopathy, current AHA/ACC guidance has moved away from blanket bans on exercise. Many patients are encouraged to be active, but high-intensity competitive sports and certain activities are discussed individually with the cardiologist.
• In arrhythmogenic cardiomyopathy, intense or endurance exercise can speed up the disease and trigger dangerous rhythms; major guidelines describe avoidance of high-intensity sports as part of management.

Your cardiologist can advise on what level of activity is appropriate for you.

Weight, Sleep, and Stress

• Maintain a healthy weight. Excess weight increases the load on the heart and is linked to worse outcomes.
• Treat sleep apnoea. Obstructive sleep apnoea is common in heart failure and contributes to rhythm problems and worsening function. If snoring, daytime sleepiness, or witnessed pauses in breathing are an issue, ask for assessment.
• Daily weights. Many heart failure programmes ask patients to weigh themselves at the same time each day. A sudden rise (for example, more than 2 kg in 2–3 days) often signals fluid build-up and should be reported.
• Stress management. Sleep, social support, and mental health all affect heart health. Anxiety and depression are common after a serious cardiac diagnosis and deserve treatment in their own right.

Smoking and Other Substances

Stopping smoking is one of the most consistently beneficial steps for cardiovascular health. Support to stop is available through your medical team. Recreational drugs that affect the heart — cocaine, amphetamines, and others — should be avoided. If you take any over-the-counter medicines or supplements, check with your cardiologist or pharmacist before starting them, as some can interact with heart medications.

Vaccinations

Patients with cardiomyopathy and heart failure are generally encouraged to keep routine vaccinations up to date, including annual influenza vaccination and other vaccines as recommended by your doctor. Respiratory infections can trigger worsening heart failure.

Monitoring and Follow-Up

Cardiomyopathy management is built around ongoing review. The frequency of visits and tests depends on stability and the type of cardiomyopathy.

• Stable patients often see their cardiologist every 6 to 12 months, with more frequent reviews after medication changes or hospital admissions.
• An echocardiogram is typically repeated periodically — the interval depends on the cardiomyopathy type and any changes in symptoms.
• Blood tests for kidney function, electrolytes, and heart strain markers (such as NT-proBNP) are commonly checked at intervals.
• If you have an implanted device, it is checked at regular intervals; many devices send information remotely.
• Family screening is recommended in inherited cardiomyopathies. This typically includes clinical assessment, ECG, and echocardiogram for first-degree relatives, sometimes alongside genetic testing.

Typical first-year cardiomyopathy follow-up timeline showing: ① diagnosis and baseline tests, ② medication titration visits (weeks 2–12), ③ first echocardiogram review (3–6 months), ④ blood tests and device check (6 months), ⑤ cardiology review and echo (12 months), ⑥ family screening.

*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.

Complications

Cardiomyopathy can lead to several complications, especially if not managed actively. Understanding these helps you and your family know what to watch for.

• Heart failure. Difficulty breathing, fatigue, swelling, and reduced exercise capacity due to the heart not pumping or filling well.
• Arrhythmias. Including atrial fibrillation (which can cause palpitations and increase clot risk) and ventricular arrhythmias (which can be life-threatening).
• Blood clots and stroke. Sluggish blood flow in a weakened or fibrillating heart raises the risk of clots that can travel to the brain or other organs. Anticoagulants are used when appropriate.
• Sudden cardiac death. A risk in certain cardiomyopathies, particularly HCM and ARVC, and in advanced heart failure. Risk assessment and ICDs are used to reduce this risk in selected patients.
• Valve problems. Stretched or thickened heart chambers can cause valves to leak.
• Kidney and liver effects. Long-standing heart failure can affect other organs.

Most of these complications can be reduced with consistent treatment, monitoring, and prompt response to changes.

Living with Cardiomyopathy

A cardiomyopathy diagnosis affects more than your heart. It shapes daily decisions, work, relationships, and how you think about the future. Many people, with the right plan, continue to lead full lives.

Work and Daily Activities

Whether you can return to your previous work, and at what level, depends on your heart function, symptoms, and the demands of the job. Office and light work are usually possible for most stable patients. Heavy physical work, high-risk occupations (such as professional driving with certain rhythm conditions), and roles requiring extreme exertion may need adjustment. Your cardiologist can guide what is appropriate.

Driving

After certain events — fainting, ICD shocks, or admission with worsening heart failure — there are usually temporary restrictions on driving. The rules depend on the country, the type of licence (private versus commercial), and the clinical situation. Ask your team for specific advice that applies to you.

Pregnancy

Pregnancy puts significant additional load on the heart. For women with cardiomyopathy, pregnancy planning should involve a cardiologist with experience in this area, ideally before conception. Some cardiomyopathies and some medications carry significant pregnancy risks; others are compatible with carefully monitored pregnancy. Contraception choices should also be discussed, as some hormonal methods may not be suitable.

Travel

Most stable patients can travel safely. Practical steps include carrying a clear list of medications and a summary of your diagnosis, keeping medications in hand luggage, and discussing long-haul flights and high-altitude destinations with your cardiologist. If you have an ICD, you may need a device identification card for airport security.

Sex and Intimacy

Sexual activity is generally safe for stable patients with cardiomyopathy. If you have symptoms with mild to moderate exertion, or after a recent hospital admission, talk with your cardiologist about when and how to resume activity. Some heart medications can affect sexual function, and adjustments may be possible.

Mental Health

Anxiety, low mood, and post-traumatic stress symptoms are common after a serious cardiac diagnosis or event, especially after ICD shocks or hospital admissions. These are treatable. Many cardiology and rehabilitation programmes include psychological support, and counselling and medication can both help.

Family and Genetic Counselling

If you have an inherited cardiomyopathy, screening of first-degree relatives (parents, siblings, children) is usually recommended. Genetic counselling helps families understand the testing process, what results may mean, and the implications for children. Identifying affected relatives early allows protective treatment to start before symptoms develop.

Cardiomyopathy in Children

Cardiomyopathy is much less common in children than in adults, but it does occur, and the management has some important differences. Childhood cardiomyopathy can be present from birth or develop later, and can be due to inherited gene changes, metabolic or neuromuscular conditions, viral myocarditis, congenital heart disease, or chemotherapy.

Children are typically cared for in specialised paediatric cardiology centres. The general principles — medications to support heart function, treatment of arrhythmias, devices in selected cases, and consideration of transplantation in advanced disease — are similar, but doses, drug choices, and surgical decisions are different. Genetic testing is often part of the evaluation, and screening of siblings and parents is commonly recommended.

Day-to-day issues for families often centre on activity recommendations at school and in sport, school support, growth and nutrition, vaccinations, and the emotional impact on the child and siblings. As children with cardiomyopathy reach adolescence, a structured transition to adult cardiology services helps continuity of care. Family counselling and connection with other families living with paediatric cardiomyopathy can be a meaningful source of support.

Preventing Complications and Progression

Even when cardiomyopathy cannot be cured, much can be done to slow progression and reduce complications.

• Take medications as prescribed, every day. If side effects are an issue, raise it rather than stopping.
• Keep follow-up appointments and complete recommended tests.
• Control blood pressure, diabetes, and cholesterol consistently if you have these conditions.
• Maintain a healthy weight and activity pattern appropriate to your cardiomyopathy.
• Avoid alcohol excess and recreational drugs; stop smoking.
• Treat sleep apnoea if it is present.
• Vaccinate against influenza and other infections as recommended.
• Recognise warning signs early and contact your team rather than waiting.
• Encourage first-degree relatives to undergo screening if your cardiomyopathy is inherited.

When to Seek Urgent Care

Contact your cardiology team promptly — or seek emergency care — for any of the following:

• Severe shortness of breath, especially at rest or when lying down
• Chest pain or pressure
• Fainting or near-fainting
• An ICD shock, even if you feel well afterwards
• Sudden, rapid weight gain or marked new swelling
• A very fast or irregular heartbeat that does not settle
• Signs of stroke: sudden weakness on one side, drooping of the face, slurred speech, or sudden vision change
• High fever or signs of serious infection

It is better to call and be reassured than to wait at home with a worsening problem.

Frequently Asked Questions

Can cardiomyopathy be cured?

For most types, cardiomyopathy is a long-term condition that is controlled rather than cured. Some forms can improve substantially or even reverse — for example, takotsubo cardiomyopathy, some cases of peripartum cardiomyopathy, alcohol-related cardiomyopathy after stopping alcohol, and certain inflammatory or chemotherapy-related forms when the trigger is removed and treatment is started early. Even when the underlying disease persists, modern medication and device therapy can produce major and lasting improvement in heart function for many patients.

Will I need a heart transplant?

Most patients with cardiomyopathy never need a transplant. Transplantation is reserved for advanced disease that has not responded to other treatments and is offered after careful evaluation of overall health.

Is cardiomyopathy genetic? Should my family be tested?

Many cardiomyopathies have a genetic component, particularly hypertrophic and arrhythmogenic forms and a significant share of dilated cardiomyopathy. Genetic testing and screening of close relatives are commonly recommended in these cases. Your cardiologist or a genetic counsellor can guide the process.

Can I exercise with cardiomyopathy?

Most patients can and should be physically active, but the type and intensity depend on the cardiomyopathy type, current heart function, and rhythm status. Cardiac rehabilitation programmes provide a safe, supervised way to build up activity. High-intensity competitive sport needs individual discussion, particularly in HCM and ARVC.

Will I be able to work?

Many people with cardiomyopathy continue to work, sometimes with adjustments to the role or hours. The specifics depend on your symptoms, heart function, and the demands of the job. Your cardiologist can advise.

What is ejection fraction, and what number should I aim for?

Ejection fraction (EF) is the percentage of blood the main pumping chamber pushes out with each beat. A normal EF is around 55 to 70 percent. In dilated cardiomyopathy, EF is often reduced, and a major aim of treatment is to improve and stabilise it. The “target” for any individual depends on the type of cardiomyopathy and the starting EF. Your team will use EF together with symptoms and other measurements rather than as a single number.

Do I need to weigh myself every day?

Daily weighing is commonly recommended for patients with heart failure as an early signal of fluid retention. A sudden rise often prompts a diuretic adjustment that can prevent hospital admission. Ask your team whether daily weighing is right for you.

Can I take supplements or traditional medicines alongside my heart medication?

Some supplements and herbal preparations interact with heart medications or affect the heart directly. Always check with your cardiologist or pharmacist before starting anything new, including products marketed as “natural” or “for the heart.”

What does an ICD shock feel like and what should I do?

An ICD shock is often described as a sudden, strong thump or kick in the chest. After any shock — even if you feel fine afterwards — contact your cardiology or device team. If you receive multiple shocks in a short period, or lose consciousness, seek emergency care.

Can children with cardiomyopathy lead normal lives?

Many children with cardiomyopathy do well with the right medical care, careful activity guidance, and family support. Outcomes depend on the type and severity, but specialised paediatric cardiology centres now offer a wide range of treatment options including medications, devices, and transplantation when needed.

Conclusion

Cardiomyopathy is a serious diagnosis, but it is one that modern cardiology is increasingly able to manage well. The shape of care depends on the type of cardiomyopathy you have, how the heart is functioning, your symptoms, and your wider health. For most patients, management is a long-term partnership with a cardiology team built around medications, lifestyle changes, careful monitoring, and — for some — devices or procedures. With consistent treatment, attention to warning signs, and screening of family members where the condition is inherited, many people with cardiomyopathy live full and active lives. The next steps in your care belong in a personal conversation with your cardiologist, who knows the details of your heart and your situation.